Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
CCR Focus

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz and John M. Lambert
Veronique Blanc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Bousseau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Caron
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Carrez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Lutz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Lambert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-11-0485 Published October 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Pattern of expression of CD19 and CD20 antigens during B-cell development and associated malignancies. A simplified cartoon of B-cell lineage, B-cell malignancies, and antigen expression (59, 60). The positioning of the different B-cell malignancies associated with different stages of B-cell development is abridged and illustrative only; a detailed description is beyond the scope of this review.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Structure of SAR3419. Figure is adapted from Al-Katib et al. (43).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Kinetics of pharmacodynamic markers p-histone H3 and cleaved caspase 3 (C-Caspase 3) in Ramos xenograft model. Quantitative evaluation of p-Histone H3 and C-Caspase 3 by image analysis quantification at 6, 24, 48, 72, and 96 hours after administration of a single intravenous dose of 20 mg/kg of SAR3419 in SCID mice bearing established Ramos subcutaneous xenograft tumors.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Kinetics of the production of nonproteic maytansinoid metabolites in the Ramos xenograft model. Quantitative evaluation of nonproteic maytansinoid metabolites (metabolites not linked to proteins) in nanograms per gram of tumor (ng Eq/g) at 2, 6, 8, 24, and 48 hours after administration of a single intravenous dose of 15 mg/kg of [3H]-SAR3419 in SCID mice bearing established Ramos xenograft tumors.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Impact of naked huB4 antibody on the efficacy of a single administration of SAR3419 against a bulky Ramos subcutaneous tumor xenograft model. SCID mice were inoculated with Ramos tumor cells, and once the xenografts had reached about 295 mm3 on day 11, mice (6 per group) were treated with a test article given by intravenous injection (tail vein). The huMy9-6 (anti-CD33 antibody) is an isotype-matched, nonspecific control humanized IgG1 antibody; huB4 is the anti-CD19 humanized IgG1 antibody moiety of SAR3419; huB4-DM4 is a synonym for SAR3419.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Longitudinal monitoring of SAR3419 activity using FDG-PET in mice inoculated intravenously with Daudi lymphoma. Samples of serial FDG-PET images obtained in mice bearing disseminated lymphoma treated on day 24 with SAR3419 or control treatment. The metabolic activity is coded on a color scale from blue (low radioactive tracer uptake) to red (high uptake). The tracer accumulates in elimination organs (urinary bladder), nonspecific sites (adipose tissues), and FDG-avid tumor tissues (depicted by white arrows).

Tables

  • Figures
  • Table 1.

    Clinical trials and discovery projects targeting CD19

    Biologic compoundTypeMechanism of actionPhase (initiation date)
    MT-103 (blinatumomab) Micromet, Inc.Bispecific scFv anti-CD19/anti-CD3 BiTET-cell recruitment and activationI/II/III (2007) Pivotal trial for MDR+ ALL
    SAR3419 Sanofi-Aventis/ImmunoGen, Inc.Humanized anti-CD19 mAb conjugated to maytansinoid DM4ADC (tubulin binder)I/II (2007)
    MEDI-551 MedImmune/Astra-ZenecaGlycoengineered humanized anti-CD19 mAb (BioWa's Potelligent)Naked antibody high-affinity FcγRIII-enhanced ADCCI (2010)
    MOR-208/XmAb5574 Xencor/MorphosysFc engineered humanized anti-CD19 mAbNaked antibody high-affinity FcγRIII-enhanced ADCCI (2010)
    MDX-1342 Medarex/Bristol-Myers SquibbGlycoengineered fully human anti-CD19 mAb (BioWa's Potelligent)Naked antibody high-affinity FcγRIII-enhanced ADCCI (2008, on hold)
    Combotox University of Texas Southwestern/AbiogenMixture of chimeric anti-CD19 mAb HD37 and anti-CD22 mAb RFB4, both conjugated to deglycosylated ricin A-chain (HD37-dgA + RFB4-dgA)Immunotoxin conjugate with deglycosylated ricin A-chainI (2005)
    DI-B4Merck KGaA/Cancer Research UKChimeric anti-CD19 mAb monoclonal antibodyNaked antibody ADCCI (2010)
    SGN-19A Seattle GeneticsFully human anti-CD19 mAb (hBU12) conjugated to auristatin (vc-MMAE)ADC (tubulin binder)Discovery
    MDX-1206 Medarex/Bristol-Myers SquibbFully human anti-CD19 mAb (MDX1435) conjugated to duocarmycin (vc-MGBAA)ADC (DNA alkylating agent)Discovery
    AFM-11 Affimed Therapeutics AGTetravalent tandem antibody (TandAb) anti-CD19/anti-CD3T-cell recruitmentDiscovery
    AFM-12 Affimed Therapeutics AGTetravalent tandem antibody (TandAb) anti-CD19/anti-CD16NK cell recruitmentDiscovery
PreviousNext
Back to top
Clinical Cancer Research: 17 (20)
October 2011
Volume 17, Issue 20
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz and John M. Lambert
Clin Cancer Res October 15 2011 (17) (20) 6448-6458; DOI: 10.1158/1078-0432.CCR-11-0485

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz and John M. Lambert
Clin Cancer Res October 15 2011 (17) (20) 6448-6458; DOI: 10.1158/1078-0432.CCR-11-0485
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Monoclonal Antibodies beyond Rituximab for Treating B-Cell Malignancies
    • CD19 Antigen
    • Anti-CD19 Intervention
    • SAR3419 Structure and Mechanism of Action
    • SAR3419 Preclinical Activities in Different Lymphoma Models
    • Imaging SAR3419 Activity in a Mouse Model
    • SAR3419 Clinical Development
    • Conclusions
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Endpoints for Immuno-oncology Trials
  • Limitations and Challenges in Immuno-oncology Trials
  • Developing Early-Phase Combination Immunotherapy Trials
Show more CCR Focus
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement